Natera Announces Next Phase Of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests Occurring After August 2023
Portfolio Pulse from Benzinga Newsdesk
Natera, Inc. (NASDAQ:NTRA) announced the continuation of its patent infringement litigation against CareDx, seeking royalties for all future AlloSure tests post-August 2023. This follows a Jan. 2024 jury verdict awarding Natera $96.3 million for past infringements. The U.S. District Court for the District of Delaware will determine future royalties, with discovery and briefing expected to last until the end of summer 2024.
February 27, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Natera's litigation against CareDx could secure future royalties, enhancing revenue prospects post-August 2023.
The successful litigation outcome and potential future royalties from CareDx's AlloSure tests could significantly boost Natera's revenue stream, positively impacting its financial outlook and stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
CareDx faces potential financial obligations to Natera for future AlloSure tests, impacting its profit margins.
The obligation to pay royalties to Natera for future AlloSure tests could lead to increased operational costs for CareDx, negatively affecting its profitability and potentially its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90